Literature DB >> 34358766

Racial inequity in medication treatment for opioid use disorder: Exploring potential facilitators and barriers to use.

Mara A G Hollander1, Chung-Chou H Chang2, Antoine B Douaihy3, Eric Hulsey4, Julie M Donohue5.   

Abstract

BACKGROUND: Despite evidence that individuals with opioid use disorder (OUD) have a lower risk of mortality when using evidence-based medications for OUD (MOUD), only 20 % of people with OUD receive MOUD. Black patients are significantly less likely than White patients to initiate MOUD. We measured the association between various facilitators and barriers to initiation, including criminal justice, human services, and health care factors, and variation in initiation of MOUD by race.
METHODS: We used data from a comprehensive, linked data set of health care, human services, and criminal justice programs from Allegheny County in Western Pennsylvania to measure disparities in MOUD initiation by race in the first 180 days after an OUD diagnosis, as well as mediation by potential facilitators and barriers to treatment, among Medicaid enrollees. This is a cross-sectional analysis.
RESULTS: Among 6374 Medicaid enrollees who met study criteria, Black enrollees were 18.2 percentage points less likely than White enrollees to start MOUD after controlling for gender, age, and Medicaid eligibility (95 % CI: -21.5 % - -14.8 %). Each day in the emergency department or county jail was associated with a decrease in the likelihood of initiation, as was the presence of a non-OUD substance use disorder diagnosis or participation in intensive non-MOUD treatment. Mediators accounted for approximately one-fifth of the variation in initiation related to race.
CONCLUSIONS: Acute care facilities and settings in which people with OUD are incarcerated may have an opportunity to increase the use of MOUD overall and close the racial gap in initiation.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Medication treatment for opioid use disorder; Opioid use disorder; Racial disparities

Mesh:

Substances:

Year:  2021        PMID: 34358766      PMCID: PMC8464525          DOI: 10.1016/j.drugalcdep.2021.108927

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.852


  29 in total

1.  Mediation Analysis with Multiple Mediators.

Authors:  T J VanderWeele; S Vansteelandt
Journal:  Epidemiol Methods       Date:  2014-01

2.  Medication-Assisted Treatment Improves Child Permanency Outcomes for Opioid-Using Families in the Child Welfare System.

Authors:  Martin T Hall; Jordan Wilfong; Ruth A Huebner; Lynn Posze; Tina Willauer
Journal:  J Subst Abuse Treat       Date:  2016-09-17

3.  Medication for Opioid Use Disorder: A National Survey of Primary Care Physicians.

Authors:  Emma E McGinty; Elizabeth M Stone; Alene Kennedy-Hendricks; Marcus A Bachhuber; Colleen L Barry
Journal:  Ann Intern Med       Date:  2020-04-21       Impact factor: 25.391

4.  Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study.

Authors:  Marc R Larochelle; Dana Bernson; Thomas Land; Thomas J Stopka; Na Wang; Ziming Xuan; Sarah M Bagley; Jane M Liebschutz; Alexander Y Walley
Journal:  Ann Intern Med       Date:  2018-06-19       Impact factor: 25.391

5.  Association between hepatitis C virus and opioid use while in buprenorphine treatment: preliminary findings.

Authors:  Sean M Murphy; Dana Dweik; Sterling McPherson; John M Roll
Journal:  Am J Drug Alcohol Abuse       Date:  2015-01       Impact factor: 3.829

6.  Buprenorphine treatment of refractory depression.

Authors:  J A Bodkin; G L Zornberg; S E Lukas; J O Cole
Journal:  J Clin Psychopharmacol       Date:  1995-02       Impact factor: 3.153

7.  Patient characteristics associated with buprenorphine/naloxone treatment outcome for prescription opioid dependence: Results from a multisite study.

Authors:  Jessica A Dreifuss; Margaret L Griffin; Katherine Frost; Garrett M Fitzmaurice; Jennifer Sharpe Potter; David A Fiellin; Jeffrey Selzer; Mary Hatch-Maillette; Susan C Sonne; Roger D Weiss
Journal:  Drug Alcohol Depend       Date:  2013-01-18       Impact factor: 4.492

8.  Exploring opioid use disorder, its impact, and treatment among individuals experiencing homelessness as part of a family.

Authors:  Avik Chatterjee; Eun Jin Yu; Lindsay Tishberg
Journal:  Drug Alcohol Depend       Date:  2018-05-12       Impact factor: 4.492

9.  Factors associated with methadone maintenance therapy discontinuation among people who inject drugs.

Authors:  Ada Lo; Thomas Kerr; Kanna Hayashi; M-J Milloy; Ekaterina Nosova; Yang Liu; Nadia Fairbairn
Journal:  J Subst Abuse Treat       Date:  2018-08-23

10.  Association of Racial/Ethnic Segregation With Treatment Capacity for Opioid Use Disorder in Counties in the United States.

Authors:  William C Goedel; Aaron Shapiro; Magdalena Cerdá; Jennifer W Tsai; Scott E Hadland; Brandon D L Marshall
Journal:  JAMA Netw Open       Date:  2020-04-01
View more
  3 in total

1.  Disparities in Health Care Spending and Utilization Among Black and White Medicaid Enrollees.

Authors:  Jacob Wallace; Anthony Lollo; Kate A Duchowny; Matthew Lavallee; Chima D Ndumele
Journal:  JAMA Health Forum       Date:  2022-06-10

2.  A bifurcated opioid treatment system and widening insidious disparities.

Authors:  Erick G Guerrero; Hortensia Amaro; Tenie Khachikian; Mona Zahir; Jeanne C Marsh
Journal:  Addict Behav       Date:  2022-03-02       Impact factor: 4.591

3.  Utilizing telemedicine during COVID-19 pandemic for a low-threshold, street-based buprenorphine program.

Authors:  Robert Harris; Amanda Rosecrans; Meredith Zoltick; Catherine Willman; Ronald Saxton; Margaret Cotterell; Joy Bell; Ingrid Blackwell; Kathleen R Page
Journal:  Drug Alcohol Depend       Date:  2021-11-26       Impact factor: 4.492

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.